Charles River Laboratories International, Inc. (CRL) Guidance & Earnings Results
On 2026-08-05 Charles River Laboratories International, Inc. raised guidance: "Organic revenue guidance up 150bps; non-GAAP EPS guidance up $0.25 at…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRLCharles River Laboratories International, Inc.Follow CRL — free
—
Price chart with a free account
- Market cap
- 16.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | Organic revenue guidance up 150bps; non-GAAP EPS guidance up $0.25 at midpoint · full year |
| 7 May 26 | Reaffirmed | Organic revenue and non-GAAP EPS guidance reaffirmed · full year |
| 13 Jan 26 | Mixed | FY2026 organic revenue growth at least flat; non-GAAP operating margin improvement from >$100M cost savings; FX benefit 100-150 bps; DSA revenue growth expected in H2 2026. · full year |
| 6 Aug 25 | Raised | FY2025 organic revenue growth raised to (3.0%)-(1.0%) from (4.5%)-(2.5%); GAAP EPS $4.25-$4.65 from $4.35-$4.85; Non-GAAP EPS raised to $9.90-$10.30 from $9.30-$9.80 · full year |
Charles River Laboratories International, Inc. — questions
- What guidance did Charles River Laboratories International, Inc. give?
- On 2026-08-05: "Organic revenue guidance up 150bps; non-GAAP EPS guidance up $0.25 at midpoint"
- When does Charles River Laboratories International, Inc. report earnings?
- Charles River Laboratories International, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Charles River Laboratories International, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.